Case Study

Endpoint Reliability And eCOA Solutions Facilitate CNS Trial Success

Virtual Covid 19 Clinical Trial

A pharmaceutical development company based in Japan with a global reach utilized Signant's eCOA solutions and knowledge to ensure the reliability of endpoints in their phase 3 and extended-duration CNS trials. These trials presented various intricacies tied to the volume and nature of clinical outcome assessments (COAs) and rating tools utilized to support the primary endpoint.

As renowned authorities in optimizing global CNS trials, Signant came equipped with the perfect tools and proficiency, offering the research teams:

  • Services for COA selection, acquisition, translation, and integration
  • A tailored program for rater training and certification, featuring on-demand videos
  • Centralized rating and expert clinical evaluation services

Discover the influence of these solutions and Signant's expertise on trial results in this comprehensive case study.

access the Case Study!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Signant Health